Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T45457
|
||||
| Former ID |
TTDR00057
|
||||
| Target Name |
Melanocortin receptor
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10: F52.2, N48.4] | ||||
| Sexual dysfunction [ICD9: 302.7; ICD10: F52] | |||||
| Ulcerative colitis [ICD9: 556; ICD10: K51] | |||||
| Target Validation |
T45457
|
||||
| Drugs and Mode of Action | |||||
| Inhibitor | Ac-His-DNal(2)-Arg-Trp-NH2 | Drug Info | [529699] | ||
| Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2 | Drug Info | [529699] | |||
| Ac-His-DPhe(pBr)-Arg-Trp-NH2 | Drug Info | [529699] | |||
| Ac-His-DPhe(pCF3)-Arg-Trp-NH2 | Drug Info | [529699] | |||
| Ac-His-DPhe(pI)-Arg-Trp-NH2 | Drug Info | [529699] | |||
| Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 | Drug Info | [530169] | |||
| Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 | Drug Info | [530169] | |||
| Ac-YRC(Me)*EHdFRWC(Me)NH2 | Drug Info | [527529] | |||
| Ac-YRMEHdFRWG-NH2 | Drug Info | [527529] | |||
| Ac-YRMEHdFRWGSPPKD-NH2 | Drug Info | [527529] | |||
| Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 | Drug Info | [527529] | |||
| Ac-YR[CEH(pCl-dF)RWC]-NH2 | Drug Info | [527529] | |||
| Ac-YR[CEH(pF-dF)RWC]-NH2 | Drug Info | [527529] | |||
| AEKKDEGPYRMEHFRWGSPPKD | Drug Info | [527529] | |||
| Bremelanotide | Drug Info | [1725886] | |||
| C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 | Drug Info | [529226] | |||
| C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | [528082] | |||
| GPYRMEHFRWGSPPKD-NH2 | Drug Info | [527529] | |||
| MK-10 | Drug Info | [526348] | |||
| MK-11 | Drug Info | [526348] | |||
| NDP-SYSMEHFRWGKPVG | Drug Info | [527529] | |||
| Modulator | ASP-3291 | Drug Info | [550606] | ||
| References | |||||
| Ref 526348 | J Med Chem. 2002 Jun 6;45(12):2644-50.Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. | ||||
| Ref 527529 | J Med Chem. 2005 May 5;48(9):3095-8.Discovery of a beta-MSH-derived MC-4R selective agonist. | ||||
| Ref 528082 | J Med Chem. 2006 Mar 23;49(6):1946-52.Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. | ||||
| Ref 529226 | J Med Chem. 2008 Jan 24;51(2):187-95. Epub 2007 Dec 19.Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor. | ||||
| Ref 529699 | J Med Chem. 2008 Sep 25;51(18):5585-93.Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.